Wells Fargo & Company Bridge Bio Pharma, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BBIO
# of Institutions
294Shares Held
177MCall Options Held
8.72MPut Options Held
2.75M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY31.1MShares$804 Million45.4% of portfolio
-
Viking Global Investors LP25.1MShares$650 Million2.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.1MShares$364 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$322 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$157 Million67.33% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.84B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...